Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone206-788-4545
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.73 million
Profitability
Miscellaneous
Employees38
OptionableNot Optionable
Alpine Immune Sciences (NASDAQ:ALPN) Frequently Asked Questions
What is Alpine Immune Sciences' stock symbol?
Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."
How were Alpine Immune Sciences' earnings last quarter?
Alpine Immune Sciences Inc (NASDAQ:ALPN) posted its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.88) EPS for the quarter, missing the Zacks' consensus estimate of ($0.57) by $0.31. Alpine Immune Sciences had a negative net margin of 1,602.19% and a negative return on equity of 43.25%. View Alpine Immune Sciences' Earnings History.
When is Alpine Immune Sciences' next earnings date?
What price target have analysts set for ALPN?
5 equities research analysts have issued 12-month target prices for Alpine Immune Sciences' shares. Their forecasts range from $12.00 to $13.00. On average, they expect Alpine Immune Sciences' stock price to reach $12.80 in the next year. This suggests a possible upside of 121.8% from the stock's current price. View Analyst Price Targets for Alpine Immune Sciences.
What is the consensus analysts' recommendation for Alpine Immune Sciences?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alpine Immune Sciences.
Has Alpine Immune Sciences been receiving favorable news coverage?
News stories about ALPN stock have trended positive on Sunday, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Alpine Immune Sciences earned a daily sentiment score of 2.4 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the next few days.
Who are some of Alpine Immune Sciences' key competitors?
Some companies that are related to Alpine Immune Sciences include MediciNova (MNOV), Abeona Therapeutics (ABEO), Albireo Pharma (ALBO), Urovant Sciences (UROV), XBiotech (XBIT), American Brivision (Holding) (ABVC), Constellation Pharmaceuticals (CNST), Magenta Therapeutics (MGTA), OptiNose (OPTN), Aclaris Therapeutics (ACRS), Verrica Pharmaceuticals (VRCA), Evelo Biosciences (EVLO), Adamas Pharmaceuticals (ADMS), Catalyst Pharmaceuticals (CPRX) and BIOFRONTERA AG/ADR (BFRA).
Who are Alpine Immune Sciences' key executives?
Alpine Immune Sciences' management team includes the folowing people:
- Dr. Mitchell H. Gold, Exec. Chairman & CEO (Age 51)
- Dr. Stanford Peng, Exec. VP of R&D and Chief Medical Officer (Age 48)
- Dr. Mark J. Litton, Pres & COO (Age 51)
- Mr. Paul Rickey, Sr. VP & CFO (Age 40)
- Dr. Kristine Swiderek Ph.D., Sr. VP of Research
Who are Alpine Immune Sciences' major shareholders?
Alpine Immune Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (0.98%) and Hikari Power Ltd (0.89%). Company insiders that own Alpine Immune Sciences stock include Bvf Partners L P/Il, James N Topper, Janice Troha, Mitchell Gold, Robert E Conway, Tiger Management LLC and Value Fund L P Biotechnology. View Institutional Ownership Trends for Alpine Immune Sciences.
Which institutional investors are buying Alpine Immune Sciences stock?
ALPN stock was bought by a variety of institutional investors in the last quarter, including Hikari Power Ltd and Victory Capital Management Inc.. Company insiders that have bought Alpine Immune Sciences stock in the last two years include Bvf Partners L P/Il, James N Topper, Janice Troha, Mitchell Gold, Robert E Conway and Value Fund L P Biotechnology. View Insider Buying and Selling for Alpine Immune Sciences.
How do I buy shares of Alpine Immune Sciences?
Shares of ALPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alpine Immune Sciences' stock price today?
One share of ALPN stock can currently be purchased for approximately $5.77.
How big of a company is Alpine Immune Sciences?
Alpine Immune Sciences has a market capitalization of $79.89 million and generates $1.73 million in revenue each year. The biotechnology company earns $-7,780,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Alpine Immune Sciences employs 38 workers across the globe.
What is Alpine Immune Sciences' official website?
How can I contact Alpine Immune Sciences?
Alpine Immune Sciences' mailing address is 201 Elliott Avenue West Suite 230, Seattle WA, 98119. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected]
MarketBeat Community Rating for Alpine Immune Sciences (NASDAQ ALPN)
MarketBeat's community ratings are surveys of what our community members think about Alpine Immune Sciences and other stocks. Vote "Outperform" if you believe ALPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALPN will underperform the S&P 500 over the long term. You may vote once every thirty days.
